{"id":130844,"date":"2026-07-08T14:49:34","date_gmt":"2026-07-08T20:49:34","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=130844"},"modified":"2026-07-08T14:49:34","modified_gmt":"2026-07-08T20:49:34","slug":"what-is-pemvidutide-the-glp-1-glucagon-drug-for-obesity-and-fatty-liver","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/what-is-pemvidutide-the-glp-1-glucagon-drug-for-obesity-and-fatty-liver\/","title":{"rendered":"What Is Pemvidutide? The GLP-1\/Glucagon Drug for Obesity and Fatty Liver"},"content":{"rendered":"

Pemvidutide is an investigational weight-loss and liver drug that hits two hormone targets at once: GLP-1 (which curbs appetite) and glucagon (which increases energy burning and pulls fat out of the liver). It’s being developed by Altimmune and is not FDA approved, so it isn’t something you can be prescribed today. In a mid-stage obesity trial it produced about 15.6% average weight loss over roughly a year, and notably, most of that loss came from fat rather than muscle. Here’s what makes it distinctive and where it stands.<\/p>\n

The Two-Hormone Approach<\/h3>\n

Most first-generation weight-loss drugs work on a single pathway. Pemvidutide takes a dual-hormone approach with a balanced 1:1 ratio of GLP-1 and glucagon activity, and the two components do different jobs. GLP-1 suppresses appetite and slows how fast your stomach empties, the mechanism you already know from semaglutide. Glucagon adds something extra: it increases energy expenditure (how many calories your body burns) and acts directly on the liver to reduce stored fat. The idea is to mimic what diet and exercise do together, appetite reduction plus increased calorie burning.<\/p>\n

That liver effect is a big part of the pemvidutide story. Because glucagon drives fat out of the liver, the drug is being developed not just for obesity but for metabolic dysfunction-associated steatohepatitis (MASH), a serious fatty liver disease.<\/p>\n

What the Obesity Data Shows<\/h3>\n

The key obesity results come from the MOMENTUM phase 2 trial. Data presented in the journal Diabetes<\/a>, published by the American Diabetes Association in 2024, showed that participants on the highest dose lost about 15.6% of their body weight over 48 weeks, versus roughly 2% on placebo, with weight still trending downward at the end of the study. A standout finding was body composition: an analysis using MRI found that only around 22% of the weight lost came from lean mass, meaning close to 78% was fat. That’s a favorable ratio, and it addresses one of the common concerns about rapid weight loss (losing muscle along with fat).<\/p>\n

Pemvidutide is given as a once-weekly injection. Alongside weight loss, the trials reported reductions in triglycerides, LDL cholesterol, and blood pressure.<\/p>\n

Quick Facts<\/h3>\n
\n\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Developer<\/td>\nAltimmune<\/td>\n<\/tr>\n
Type<\/td>\nGLP-1\/glucagon dual receptor agonist (1:1)<\/td>\n<\/tr>\n
Administration<\/td>\nOnce-weekly injection<\/td>\n<\/tr>\n
Status<\/td>\nInvestigational (not FDA approved)<\/td>\n<\/tr>\n
Obesity data<\/td>\nAbout 15.6% weight loss at 48 weeks (phase 2)<\/td>\n<\/tr>\n
Also studied for<\/td>\nMASH (fatty liver disease)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

The Liver Angle<\/h3>\n

Pemvidutide’s MASH program has produced encouraging signals on liver fibrosis markers, and the company has said it intends to move into phase 3 testing. Consider a hypothetical patient who has both excess weight and fatty liver disease. A drug that addresses appetite, calorie burning, and liver fat in one treatment would be appealing, which is exactly the niche pemvidutide is aiming for. That said, the MASH results have been described as mixed by some analysts, and the drug still has to prove itself in larger, longer trials.<\/p>\n

What This Means for You Right Now<\/h3>\n

Here’s the honest bottom line: pemvidutide isn’t available, and TrimRx doesn’t offer it. TrimRx provides options that are available today, including compounded semaglutide and compounded tirzepatide, along with brand medications like Ozempic, Wegovy, Mounjaro, and Zepbound. If you’re interested in weight loss now, the practical move is to look at what you can actually access rather than waiting on a drug that’s years from a possible approval, if it’s approved at all.<\/p>\n

Pemvidutide is worth watching, particularly if you’re following the fatty liver space, but it’s a future prospect, not a current option.<\/p>\n

Frequently Asked Questions<\/h3>\n

Is pemvidutide FDA approved?<\/h4>\n

No. Pemvidutide is investigational and has not been approved by the FDA for any use. It has completed mid-stage (phase 2) trials for obesity and is being studied in phase 2b for MASH, with phase 3 testing planned. It’s only available to people enrolled in clinical trials.<\/p>\n

How does pemvidutide compare to semaglutide?<\/h4>\n

Semaglutide targets GLP-1 alone, while pemvidutide adds glucagon activity to increase energy expenditure and reduce liver fat. In its phase 2 trial pemvidutide produced about 15.6% weight loss, and its data suggested strong preservation of muscle mass, though the two haven’t been compared head-to-head in a single trial.<\/p>\n

Can I get pemvidutide from TrimRx?<\/h4>\n

No. TrimRx offers medications that are currently available, such as compounded semaglutide and tirzepatide and brand GLP-1 options. Pemvidutide is not among them because it isn’t approved or available outside of clinical trials.<\/p>\n

If you want to focus on what’s within reach today, you can explore the options available to you now<\/a> with a licensed provider.<\/p>\n

This information is for educational purposes and is not medical advice. Pemvidutide is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Pemvidutide is an investigational weight-loss and liver drug that hits two hormone targets at once: GLP-1 (which curbs appetite) and glucagon (which increases energy…<\/p>\n","protected":false},"author":7,"featured_media":130098,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[],"class_list":["post-130844","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=130844"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130844\/revisions"}],"predecessor-version":[{"id":130845,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130844\/revisions\/130845"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/130098"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=130844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=130844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=130844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}